Published Date: 06/06/2023
Expiration Date: 04/12/2026
The presence of xylazine in New York City was first noted in 2017 after an analysis of syringes obtained by the Department of Health from local syringe service programs were found to contain the substance. Since then, xylazine is increasingly being detected in overdose deaths in the City, and other counties throughout the state have noted the possible presence of xylazine in the local drug supply. In order to ensure that clinicians in New York State are prepared to provide care to patients who use xylazine, this clinical education activity will cover trends and use of xylazine, specifics of xylazine intoxication, signs of and responses to xylazine overdose and harm reduction strategies relevant to xylazine use.
Disclaimer
Effective June 27, 2023 the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) announced a one-time requirement of 8 hours of training on the treatment and management of patients with opioid or other substance use disorders for practitioners who are applying for or renewing their DEA license. This 1-hour ACCME-accredited course meets the DEA/SAMHSA requirement.
Joseph D'Orazio, MD is an emergency physician, medical toxicologist, and addiction medicine specialist at the Lewis Katz School of Medicine at Temple University. He cares for Temple patients in a variety of settings, including the emergency department, an inpatient consultative service for addiction medicine and toxicology, the TRUST Clinic (an office-based opioid treatment program), and Begin the Turn (Temple's low-barrier access street-side medicine program). Dr. D’Orazio is a medical toxicologist for the Poison Control Center at Children’s Hospital of Philadelphia and is regarded as a regional expert regarding substance use and substance use disorder treatment in Philadelphia.
